Nebojsa Lalic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6263375/publications.pdf

Version: 2024-02-01

331670 254184 1,967 51 21 43 citations h-index g-index papers 58 58 58 3152 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
2	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1724-1732.	8.6	227
3	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. European lournal of Preventive Cardiology, 2016, 23, 2007-2018.	1.8	153
4	Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Annals of Medicine, 2005, 37, 613-620.	3.8	75
5	Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. Diabetes Therapy, 2020, 11, 387-409.	2.5	68
6	Hypertension in Obese Type 2 Diabetes Patients is Associated with Increases in Insulin Resistance and IL-6 Cytokine Levels: Potential Targets for an Efficient Preventive Intervention. International Journal of Environmental Research and Public Health, 2014, 11, 3586-3598.	2.6	67
7	Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetologica, 2016, 53, 737-744.	2.5	63
8	Relationship between Obesity, Adipocytokines and Inflammatory Markers in Type 2 Diabetes: Relevance for Cardiovascular Risk Prevention. International Journal of Environmental Research and Public Health, 2014, 11, 4049-4065.	2.6	55
9	Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europeâ€"Recommendations from the International Central-Eastern European Expert Group. Diabetes Technology and Therapeutics, 2014, 16, 460-475.	4.4	54
10	Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 130, 121-129.	2.8	53
11	More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus. Annals of General Psychiatry, 2019, 32, e100076.	3.1	50
12	Influence of Hyperinsulinemia and Insulin Resistance on In Vivo \hat{I}^2 -Cell Function. Diabetes, 2011, 60, 3141-3147.	0.6	43
13	Influence of the ACE Gene Insertion/Deletion Polymorphism on Insulin Sensitivity and Impaired Glucose Tolerance in Healthy Subjects. Diabetes Care, 2008, 31, 789-794.	8.6	40
14	Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care, 2021, 44, 2361-2370.	8.6	28
15	Metabolic characteristics of prehypertension: role of classification criteria and gender. Journal of Hypertension, 2009, 27, 2394-2402.	0.5	27
16	Serum Cystatin C Levels in COPD: Potential Diagnostic Value and Relation Between Respiratory Functions. Journal of Medical Biochemistry, 2018, 37, 434-440.	1.7	26
17	Value and Utility of Structured Self-Monitoring of Blood Glucose in Real World Clinical Practice: Findings from a Multinational Observational Study. Diabetes Technology and Therapeutics, 2012, 14, 338-343.	4.4	23
18	Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS ONE, 2020, 15, e0231196.	2.5	23

#	Article	IF	CITATIONS
19	Advancing therapy with <scp>iGlarLixi</scp> versus premix BIAsp 30 in basal insulinâ€treated type 2 diabetes: Design and baseline characteristics of the <scp>SoliMix</scp> randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1221-1231.	4.4	19
20	Mineralocorticoid receptor antagonists, a class beyond spironolactone — Focus on the special pharmacologic properties of eplerenone. International Journal of Cardiology, 2015, 200, 3-7.	1.7	17
21	Hybrid Closed-Loop Systems for the Treatment of TypeÂ1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Therapy, 2021, 12, 3107-3135.	2.5	16
22	Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?. Cardiovascular Diabetology, 2018, 17, 145.	6.8	14
23	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. Diabetes Research and Clinical Practice, 2021, 172, 108535.	2.8	14
24	In vitro models of insulin resistance: Mitochondrial coupling is differently affected in liver and muscle cells. Mitochondrion, 2021, 61, 165-173.	3.4	10
25	Diabetic Microvascular Complications. International Journal of Endocrinology, 2018, 2018, 1-2.	1.5	9
26	Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. Diabetes Therapy, 2018, 9, 1201-1216.	2.5	8
27	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	6.8	8
28	Influence of IL-6, TNF- \hat{l}_{\pm} and hs-CRP on Insulin Sensitivity in Patients after Laparoscopic Cholecystectomy or Open Hernia Repair. Journal of Medical Biochemistry, 2018, 37, 328-335.	1.7	7
29	Monogenic diabetes characteristics in a transnational multicenter study from Mediterranean countries. Diabetes Research and Clinical Practice, 2021, 171, 108553.	2.8	7
30	The effect of hyperglycemia on the values of antioxidative parameters in type 2 diabetic patients with cardiovascular complications. Journal of Medical Biochemistry, 2006, 25, 173-179.	0.1	7
31	The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management. European Journal of Health Economics, 2007, 8, 97-103.	2.8	6
32	Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia. Current Vascular Pharmacology, 2016, 15, 19-29.	1.7	6
33	Maternal and Fetal Outcomes among Pregnant Women with Diabetes. International Journal of Environmental Research and Public Health, 2022, 19, 3684.	2.6	6
34	Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. Diabetes Therapy, 2018, 9, 727-741.	2.5	5
35	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 2019, 153, 30-40.	2.8	5
36	The Influence of Type And Duration of Cardiovascular Complications On Antioxidative Parameter Values In Type 2 Diabetic Patients. Journal of Medical Biochemistry, 2007, 26, 10-16.	1.7	4

#	Article	IF	CITATIONS
37	The role of glycemia in acute heart failure patients. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1437-46.	2.3	4
38	Expert Opinion: A Call for Basal Insulin Titration in Patients with TypeÂ2 Diabetes in Daily Practice: Southeast European Perspective. Diabetes Therapy, 2021, 12, 1575-1589.	2.5	4
39	Distribution of normal and pathological OGTTs among pregnant population and non-pregnant women with PCOS \hat{a} e" the cross-sectional study. Medicine (United States), 2021, 100, e27232.	1.0	4
40	Asymptomatic cardiovascular manifestations in diabetes mellitus: Left ventricular diastolic dysfunction and silent myocardial ischemia. Srpski Arhiv Za Celokupno Lekarstvo, 2011, 139, 599-604.	0.2	4
41	Use of Structured Self-Monitoring of Blood Glucose Improves Glycemic Control in Real-World Clinical Practice: Findings from a Multinational and Retrospectively Controlled Trial. Journal of Diabetes Science and Technology, 2013, 7, 285-286.	2.2	3
42	Continuing medical education in Serbia with particular reference to the Faculty of Medicine, Belgrade. Vojnosanitetski Pregled, 2015, 72, 160-168.	0.2	2
43	The Diabetic Foot. Journal of Diabetes Research, 2017, 2017, 1-2.	2.3	2
44	Correlation between coagulation and inflammation state in patients with diabetes mellitus type 2 in relation to gender differences: Is there any impact of eight-week exercise training?. Vojnosanitetski Pregled, 2019, 76, 175-185.	0.2	2
45	Chronic Diabetic Complications: Current Challenges and Opportunities. Journal of Clinical Medicine, 2022, 11, 673.	2.4	2
46	Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.	2.2	2
47	Trends of the Prevalence of Pre-gestational Diabetes in 2030 and 2050 in Belgrade Cohort. International Journal of Environmental Research and Public Health, 2022, 19, 6517.	2.6	2
48	Stenting and Surgery for Coronary Vasospasm. Herz, 2009, 34, 564-566.	1.1	0
49	A standstill continuing medical education in Serbia 2011-2017. Srpski Arhiv Za Celokupno Lekarstvo, 2021, 149, 334-342.	0.2	0
50	Effects of aerobic training on the risk of coronary artery disease by Duke Treadmill Score in type 2 diabetes mellitus and cardiometabolic health. Medicina Dello Sport, 2019, 72, .	0.1	0
51	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstýtzter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0